ChromaDex Stock Rating Decreased by StockNews.com

ChromaDex (NASDAQ:CDXC) recently faced a downgrade from StockNews.com, which moved its rating from "strong-buy" to "buy" in a report shared with clients and investors on Thursday.

In addition to StockNews.com, several other equities analysts have recently provided their insights on ChromaDex. Roth Mkm, for instance, raised its price target for ChromaDex shares from $6.00 to $8.00 while maintaining a "buy" rating in a report dated November 6th. Similarly, LADENBURG THALM/SH SH also increased its price objective from $6.80 to $8.10, affirming a "buy" rating in their own research.

ChromaDex Stock Performance

On Thursday, shares of ChromaDex experienced a decline of 10.1%, trading down by $0.86 to reach $7.69. During this trading session, a total trading volume of 2,347,862 shares was recorded, significantly surpassing the average volume of 859,920 shares. The company's 50-day moving average stands at $5.72, while the two-hundred day moving average is $5.15. Over the past year, ChromaDex's stock has seen a low of $1.57 and a high of $9.18, with a current market capitalization of approximately $587.39 million. The stock holds a price-to-earnings (P/E) ratio of 769.77 and a beta rating of 2.21.

Insider Transactions

In related news, on December 13th, Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock at an average price of $6.19, resulting in a total sale value of $230,026.59. Following this transaction, the director now holds 244,179 shares of the company, valued at around $1,511,468.01, reflecting a 13.21% decrease in their position. This sale has been duly reported in documents filed with the Securities and Exchange Commission. Currently, company insiders own about 9.64% of ChromaDex shares.

Institutional Investment Activity

Recent changes in holdings by institutional investors have also been noteworthy. For example, OneDigital Investment Advisors LLC increased its stake in ChromaDex by 5.5% within the third quarter, now owning 59,414 shares valued at $217,000 after adding 3,097 shares. Similarly, Connor Clark & Lunn Investment Management Ltd. raised its stake by 10.8%, owning 175,172 shares worth $639,000 following an acquisition of 17,115 additional shares. The Manufacturers Life Insurance Company significantly boosted its position by 75.4%, acquiring an additional 8,485 shares to reach a total of 19,732 shares valued at $72,000. Other notable moves include Millrace Asset Group Inc. purchasing a new stake valued at $93,000, and FMR LLC acquiring a new stake valued at $55,000. Overall, 15.41% of ChromaDex stock is currently held by institutional investors and hedge funds.

About ChromaDex

ChromaDex Corporation is a bioscience company dedicated to developing products for healthy aging. The company operates across three main segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. Its research focuses on nicotinamide adenine dinucleotide (NAD+), and it provides finished dietary supplement products that incorporate proprietary ingredients directly to consumers and distributors. ChromaDex also develops and commercializes proprietary-based ingredient technologies, supplying these ingredients to manufacturers of consumer products.

Stock, Rating, ChromaDex